From Medscape Rheumatology

Coverage from the

European Alliance of Associations for Rheumatology (EULAR) 2024 Annual Meeting

June 12 - 15, 2024; Vienna, Austria

June 12 - 15, 2024 Vienna, Austria

Conference News

EULAR 2024 Taper, Dose Down, Discontinue: Striving for Less Steroid Use
Medscape Medical News, July 25, 2024
EULAR 2024 Breaking Rheumatology's Reliance on Steroids: New Strategies
Medscape Medical News, July 25, 2024
EULAR 2024 Careful Steroid Tapering May Not Increase SLE Flares
Medscape Medical News, July 11, 2024
EULAR 2024 New Gout Drugs Might Increase Patients at Target Urate Level
Medscape Medical News, July 9, 2024
EULAR 2024 New Data Support CAR T Cells in Difficult Rheumatic Diseases
Medscape Medical News, July 8, 2024
EULAR 2024 Osteoporosis Medication Could Soothe Arthritic Fingers
Medscape Medical News, July 8, 2024
EULAR 2024 Axial Involvement in PsA Still Defies Definition
Medscape Medical News, July 2, 2024
EULAR 2024 Patient-Initiated Care Works Well in Spondyloarthritis
Medscape Medical News, June 28, 2024
EULAR 2024 Canakinumab Effective as Steroid-Free, First-Line sJIA Drug
Medscape Medical News, June 26, 2024
EULAR 2024 Updated SSc Recommendations Use 'Therapeutic Continuums'
Medscape Medical News, June 25, 2024
EULAR 2024 Osteoarthritis Drugs Need Trials With Appropriate Endpoints
Medscape Medical News, June 21, 2024
EULAR 2024 Phase 3 Trial Supports Ixekizumab in Juvenile PsA, ERA
Medscape Medical News, June 20, 2024

EULAR 2024 Nurse-Led Care for Gout Generates Best Uric Acid Control
Medscape Medical News, June 20, 2024
EULAR 2024 Izokibep Enthesitis Benefit Lacking in Phase 2b/3 PsA Trial
Medscape Medical News, June 19, 2024
EULAR 2024 Psoriatic Arthritis Drugs Comparably Improve Joint Outcomes
Medscape Medical News, June 19, 2024
EULAR 2024 New JAK 1 Inhibitor Proves Promising in Phase 3 RA Trial
Medscape Medical News, June 19, 2024
EULAR 2024 Lifestyle Changes Still Net Benefits in OA, RA After 2 Years
Medscape Medical News, June 18, 2024
EULAR 2024 Treat Gout to Target Based on Uric Acid Level, Not Symptoms
Medscape Medical News, June 18, 2024
EULAR 2024 No Detriment to RA Starting MTX a Month After PCV13
Medscape Medical News, June 17, 2024
EULAR 2024 Upadacitinib Improves Giant Cell Arteritis in Phase 3 Trial
Medscape Medical News, June 14, 2024
EULAR 2024 Anti-Ro/SSA Antibodies Have Potential to Predict ILD in SSc
Medscape Medical News, June 14, 2024
EULAR 2024 Real-World RA Data Find JAK Inhibitor Infection Risk Is Low
Medscape Medical News, June 14, 2024
EULAR 2024 EULAR 2024 Preview: What's Not-to-Miss?
Medscape Medical News, June 10, 2024

Medscape Rheumatology©

Perspectives

Key Data in Rheumatoid Arthritis From EULAR 2024
Jeffrey Sparks, MD, MMSc

Popular News From EULAR 2023

Two Biologics Show No Difference in Axial Spondyloarthritis This study represents the first head-to-head trial comparing the effects of two biologics in axial spondyloarthritis, in this case in patients at high risk for radiographic progression.
Medscape Medical News, Jun 01, 2023
Early AxSpA Diagnosis Stable in Most Referred Patients Patients who are diagnosed with axial spondyloarthritis after referral to a rheumatologist for chronic back pain most often keep that diagnosis, providing good reason to refer patients early.
Medscape Medical News, Jun 05, 2023
EULAR PsA Update Emphasizes Safety, Non-MSK Manifestations The update builds on 2019 recommendations and incorporates safety concerns about JAK inhibitors, advises on differential drug efficacy across disease manifestations, and eliminates systemic steroids.
Medscape Medical News, Jun 09, 2023

Previous Coverage

Related Resources

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.